accommodate all requests, the ASC may refuse attendance on that reasonable basis. The use of any video or audio tape recording device, photographing device, or any other electronic or mechanical device designed for similar purposes is prohibited at ASC meetings.

Dated: September 26, 2013.

James R. Park,
Executive Director.

[FR Doc. 2013–23985 Filed 10–1–13; 8:45 am]

BILLING CODE 6700–01–P

FEDERAL FINANCIAL INSTITUTIONS EXAMINATION COUNCIL

[Docket No. AS13–23]

Appraisal Subcommittee Meeting

AGENCY: Appraisal Subcommittee of the Federal Financial Institutions Examination Council.

ACTION: Notice of meeting.

SUMMARY: In accordance with Section 1104(b) of Title XI of the Financial Institutions Reform, Recovery, and Enforcement Act of 1989, as amended, notice is hereby given that the Appraisal Subcommittee (ASC) will meet in closed session:

DATES: October 9, 2013.

ADDRESSES: 400 7th Street SW., Washington, DC 20024.

SUPPLEMENTARY INFORMATION:
Location: OCC—400 7th Street SW., Washington, DC 20024
Date: October 9, 2013
Time: Immediately following the ASC open session
Status: Closed

Matters To Be Considered

September 11, 2013 minutes—Closed Session
Preliminary discussion of State Compliance Reviews

Dated: September 26, 2013.

James R. Park,
Executive Director.

[FR Doc. 2013–23986 Filed 10–1–13; 8:45 am]

BILLING CODE 6700–01–P

FEDERAL RESERVE SYSTEM

Change in Bank Control Notices; Acquisitions of Shares of a Bank or Bank Holding Company

The notificants listed below have applied under the Change in Bank Control Act (12 U.S.C. 1817(j)) and § 225.41 of the Board’s Regulation Y (12 CFR 225.41) to acquire shares of a bank or bank holding company. The factors that are considered in acting on the notices are set forth in paragraph 7 of the Act (12 U.S.C. 1817(j)(7)).

The notices are available for immediate inspection at the Federal Reserve Bank indicated. The notices also will be available for inspection at the offices of the Board of Governors. Interested persons may express their views in writing to the Reserve Bank indicated for that notice or to the offices of the Board of Governors. Comments must be received not later than October 16, 2013.

A. Federal Reserve Bank of Kansas City (Dennis Denney, Assistant Vice President) 1 Memorial Drive, Kansas City, Missouri 64198–0001:

1. Glory Burns, Fort Collins, Colorado, Robin Isham, Templeton, California, Andrea Voss, Chadron, Nebraska, Julie Jennings, Lone Tree, Colorado, and R. Will Isham, Gordon, Nebraska, individually and as trustees of the E. Joy Isham Irrevocable Trust, and the Ralph W. Marital Deduction Testamentary Trust, both of Gordon, Nebraska, all as members of the Isham Family Group, to retain voting shares of Isham Management Company, and thereby indirectly retain voting shares of The First National Bank of Gordon, both in Gordon, Nebraska.

Board of Governors of the Federal Reserve System, September 26, 2013.

Margaret McCloskey Shanks,
Deputy Secretary of the Board.

[FR Doc. 2013–23986 Filed 10–1–13; 8:45 am]

BILLING CODE 6101–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Office of the Secretary

Findings of Research Misconduct

AGENCY: Office of the Secretary, HHS.

ACTION: Notice.

SUMMARY: Notice is hereby given that the Office of Research Integrity (ORI) has taken final action in the following case:

Nitin Aggarwal, Ph.D., Medical College of Wisconsin and University of Wisconsin-Madison: Based on the reports of the investigations conducted by the Medical College of Wisconsin (MCW) and the University of Wisconsin-Madison (UW) and additional analysis conducted by the ORI in its oversight review, ORI found that Dr. Nitin Aggarwal, former Graduate Student, MCW, and former Assistant Scientist, UW, engaged in research misconduct in research supported by National Heart, Lung, and Blood Institute (NHLBI), National Institutes of Health (NIH), grants R01 HL37081, R01 HL54075, and R01 HL57414.

ORI found that that the Respondent engaged in research misconduct by falsifying and/or fabricating data supported in data in (6) figures that were included in the following two (2) publications, one (1) grant application to the American Heart Association (AHA), one (1) grant application to NIH, and the Respondent’s Ph.D. thesis:

• Aggarwal, N.T., Pfister, S.L., & Campbell, W.B. “Hypercholesterolemia Enhances 15-Lipoxygenase Mediated Vasorelaxation and Acetylcholine-Induced Hypotension.” Arteriosclerosis, Thrombosis, and Vascular Biology 28:2209–2215, 2008 (hereafter the ATVB paper).
• Aggarwal, N.T., Pfister, S.L., Gauthier, K.M., Chawengsub, Y., Baker, J.E., & Campbell, W.B. “Chronic hypoxia enhances 15-lipoxygenase-mediated vasorelaxation in rabbit arteries.” American Journal of Physiology—Heart Circulation Physiology 296:H678–H688, 2008 (hereafter the AJP paper).

Aggarwal, N.T., Principal Investigator (P.I.), National Scientist Development grant application to the American Heart Association No. 11SDG7650072, “Sulfonlyurea rReceptor-2 splice variant and mitochondrial mechanisms for cardioprotection and arrhythmia” (hereafter the AHA grant application).

K90 HL113518–01, “Mitochondrial ATP-sensitive K-channels and pharmacological approaches for cardioprotection,” Aggarwal, Nitin, Ph.D., P.I.

Aggarwal, N.T. “Endothelial 15-lipoxygenase regulates vasorelaxation and blood pressure in rabbits in normal and pathological conditions.” A Dissertation Submitted to the Faculty of the Graduate School of Biomedical Science of the Medical College of Wisconsin in Partial Fulfillment of the Requirements for the Degree of Doctor of Philosophy, Milwaukee, Wisconsin, 2008 (hereafter the thesis).

Specifically, ORI found that Respondent engaged in research misconduct by falsifying Western blot loading control data by inverting, duplicating, and cropping source blot films and/or using films from unrelated experiments to construct five (5) false Western blot figures. In the absence of valid blot images, Respondent falsified and/or fabricated the corresponding quantitative data for summary bar graphs and the data statistics in related text. Respondent failed to falsely reporting the number of mice reported for an experiment reported in Figure 4.
in grant application HL113518–01 to support the hypothesis of the research. The falsified and/or fabricated data are:

- False β-actin data and statistics in Figures 1A and 1B in the AJP paper and Figures 41A and 41B in the thesis (p. 131) that purport to represent a time-course of 15–LO–1 protein expression in rabbit aortic endothelial cells (RAECs) following hypoxia.
- False β-actin and 15–LO–1 data and statistics in Figures 2A and 2B in the AJP paper and Figures 45A and 45B in the thesis (p. 135) that purport to represent 15–LO–1 expression in aortic rings of normoxic and hypoxic rabbits.
- False β-actin data and statistics in Figures 3A and 3B in the AJP paper and Figures 46A and 46B in the Respondent’s Ph.D. thesis (p. 137) that purport to represent 15–LO–1 expression in different arteries after hypoxia.
- False β-actin data and statistics in Figures 1A and 1B in the ATVB paper and Figures 26A and 26B in the thesis (p. 105) that purport to demonstrate changes in 15–LO–1 expression in different arteries of cholesterol-animals; the false β-actin data in Figure 1A. ATVB was the same image as that used for Figure 1A. AJP but flipped vertically.
- False GAPDH data and statistics in Figure 7 in the AHA grant application that purport to represent SUR2A–55 expression in murine heart following left ventricular hypertrophy (LVH).
- False reporting in Figure 4A of grant application HL113518–01 for the number of mice used for the physiological data for ATP-induced potassium influx in murine mitochondria as three to four, when only a single mouse was studied.

Dr. Aggarwal has entered into a Voluntary Settlement Agreement and has voluntarily agreed for a period of three (3) years, beginning on September 17, 2013:

1. To have his research supervised; Respondent agreed that prior to the submission of an application for U.S. Public Health Service (PHS) support for a research project on which his participation is proposed and prior to his participation in any capacity on PHS-supported research, Respondent shall ensure that a plan for supervision of his duties is submitted to ORI for approval; the supervision plan must be designed to ensure the scientific integrity of his research contribution; he agreed that he shall not participate in any PHS-supported research until such a supervision plan is submitted to and approved by Respondent agreed to maintain responsibility for compliance with the agreed upon supervision plan;
2. that any institution employing him shall submit in conjunction with each application for PHS funds, or report, manuscript, or abstract involving PHS-supported research in which Respondent is involved, a certification to ORI that the data provided by Respondent are based on actual experiments or are otherwise legitimately derived, and that the data, procedures, and methodology are accurately reported in the application, report, manuscript, or abstract; and
3. to exclude himself voluntarily from serving in any advisory capacity to PHS including, but not limited to, service on any PHS advisory committee, board, and/or peer review committee, or as a consultant.

FOR FURTHER INFORMATION CONTACT:

David E. Wright,
Director, Office of Research Integrity.
[FR Doc. 2013–23971 Filed 10–1–13; 8:45 am]

BILLING CODE 4150–31–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

[CDC–2013–0015; NIOSH–237–A]

National Institute for Occupational Safety and Health Personal Protective Technology Program and National Personal Protective Technology Laboratory Conformity Assessment; Extension of Comment Period

AGENCY: The National Institute for Occupational Safety and Health (NIOSH) of the Centers for Disease Control and Prevention (CDC), Department of Health and Human Services (HHS).

ACTION: Notice and extension of comment period.

SUMMARY: On August 14, 2013, the Director of the National Institute for Occupational Safety and Health (NIOSH) of the Centers for Disease Control and Prevention (CDC) published a notice in the Federal Register [78 FR 49524] announcing a public meeting. This meeting was held on September 17, 2013 to provide (1) a summary of the work conducted by the NIOSH Personal Protective Technology (PPT) Conformity Assessment Working Group (PCAWG), (2) provide an overview of model Conformity Assessment programs, and (3) solicit input to define a national framework for PPE conformity assessment.

NIOSH’s National Personal Protective Technology Laboratory (NPPTL) is addressing recommendations of the Institute of Medicine (IOM) and the National Research Council based on a review of NPPTL’s program activities. The IOM report identified gaps and inconsistencies in the certification and other conformity assessment processes for non-respiratory PPT. Conformity assessment is defined as the “demonstration that specified requirements relating to a product, process, system, person or body are fulfilled.” Conformity assessment processes for PPT products are focused on product effectiveness and include the following primary components: Certification (ISO/IEC 17065), Inspection (ISO/IEC 17020), Testing (ISO/IEC 17025), Accreditation (ISO/IEC 17011), Surveillance (ISO/IEC 17011, ISO/IEC 17065), Supplier’s Declaration of Conformity (ISO/IEC 17050), Registration (ISO/IEC 17021) and Quality management systems (ISO/ 9001).

Written comments were to be received by September 30, 2013. NIOSH is extending the public comment period to December 2, 2013.

You may submit comments by either of the following methods:

- Federal eRulemaking Portal: http://www.regulations.gov. Follow the instructions for submitting comments.
- Mail: NIOSH Docket Office, Robert A. Taft Laboratories, MS–C34, 4676 Columbia Parkway, Cincinnati, OH 45226.

All information received in response to this notice and meeting must include the agency name and docket number (CDC–2013–0015; NIOSH–237–A). All relevant comments received will be posted without change to http://www.regulations.gov, including any personal information provided. All information will be available for public examination and copying at the NIOSH Docket Office, 4676 Columbia Parkway, Room 109, Cincinnati, OH 45226. All electronic comments should be formatted in Microsoft Word.

To view the notice and related materials, visit http://www.regulations.gov and enter CDC–2013–0015 in the search field and click “Search.”

FOR FURTHER INFORMATION CONTACT:

Richard Metzler, General Engineer, NIOSH at NPPTLEvents@cdc.gov; telephone (412) 386–6686, fax (412) 386–6617.